ERBA Diagnostics Enters Brazilian Sector with Leading-Edge Clinical Testing Portfolio
|
By LabMedica International staff writers Posted on 02 Nov 2014 |
|
ERBA Diagnostics, Inc. (Miami Lakes, FL, USA) has announced that an integrated portfolio of its latest in vitro diagnostics platforms and reagents are now being made available to hospitals, references labs, and physician clinics in Brazil. The product line includes a comprehensive suite of instruments, reagents, and kits for immunology, clinical chemistry, hematology, diabetes, and infectious disease testing, with an emphasis on hematology and clinical chemistry. ERBA Diagnostics intends to introduce this suite of products as the product registrations in Brazil are completed.
"We believe that our line of products is ideally suited to address the rapidly growing medical needs for Brazil," said Mohan Gopalkrishnan, chief executive officer of ERBA Diagnostics, "Within Brazil, there is a predominance of smaller, local healthcare providers. We expect that our proprietary instruments and reagents will allow these providers access to the latest diagnostics at a scale and price point that serves their needs. Our initial experience in Brazil during the past three months has been encouraging and we look forward to expanding the number of clinics and hospitals we serve, as we continue to register the full suite of our products in Brazil."
The estimated market for in vitro diagnostics products in Brazil was approximately USD 1.0 billion in 2012 and is expected to grow to USD 1.4 billion by 2017, far exceeding the rate of growth in the world market for in vitro diagnostics products. Brazil has a population of 200 million people and the country is undergoing a rapid expansion of the elderly and middle class. These factors are contributing to the increased demand for clinical testing at both public and private healthcare providers as a means to inform treatment, improve outcomes, and reduce overall healthcare expenditures.
"Given our commitment to Brazil, and as part of our continued effort to streamline our operations, we are evaluating opportunities to establish local manufacturing capabilities," added Mr. Gopalkrishnan, "We believe that establishing manufacturing capabilities in Brazil will ultimately allow us to operate as efficiently as possible while simultaneously positioning us to best serve the diagnostic testing needs of the country's healthcare providers."
Related Links:
ERBA Diagnostics
 Assay.jpg)
"We believe that our line of products is ideally suited to address the rapidly growing medical needs for Brazil," said Mohan Gopalkrishnan, chief executive officer of ERBA Diagnostics, "Within Brazil, there is a predominance of smaller, local healthcare providers. We expect that our proprietary instruments and reagents will allow these providers access to the latest diagnostics at a scale and price point that serves their needs. Our initial experience in Brazil during the past three months has been encouraging and we look forward to expanding the number of clinics and hospitals we serve, as we continue to register the full suite of our products in Brazil."
The estimated market for in vitro diagnostics products in Brazil was approximately USD 1.0 billion in 2012 and is expected to grow to USD 1.4 billion by 2017, far exceeding the rate of growth in the world market for in vitro diagnostics products. Brazil has a population of 200 million people and the country is undergoing a rapid expansion of the elderly and middle class. These factors are contributing to the increased demand for clinical testing at both public and private healthcare providers as a means to inform treatment, improve outcomes, and reduce overall healthcare expenditures.
"Given our commitment to Brazil, and as part of our continued effort to streamline our operations, we are evaluating opportunities to establish local manufacturing capabilities," added Mr. Gopalkrishnan, "We believe that establishing manufacturing capabilities in Brazil will ultimately allow us to operate as efficiently as possible while simultaneously positioning us to best serve the diagnostic testing needs of the country's healthcare providers."
Related Links:
ERBA Diagnostics
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Automated Coagulation Analyzer
Hemolumi H6
Rapid Sepsis Test
SeptiCyte RAPID
Latest Industry News
- Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition
- Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
- Seed Amplification Test Expands Access to Neurodegenerative Disease Testing
- Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
- Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
- Merck KGaA to Acquire Bio-Techne, Expanding Life Science Portfolio
- Agilent Strengthens Pathology Capabilities Through Biocare Acquisition
- Partnership Integrates Automated DNA Extraction with Single-Molecule Digital PCR
- Project Aims to Develop First Single-Cell Assay for ADC Therapies
- Agreement Supports pTau217-Based Alzheimer’s Blood Test Development
- Collaboration Aims to Broaden Access to NETosis-Linked Disease Testing
- Partnership Aims to Improve Transplant Monitoring Across Care Continuum
- QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
- Partnership Expands Ultrasensitive Blood-Based Diagnostics for Hematologic Malignancies
- Genetic Testing Program Expands Detection of Alpha-1 Antitrypsin Deficiency
- Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Channels
Clinical Chemistry
view channel
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read more
Ultrasensitive Biosensor Detects Early Liver Fibrosis from Blood
Early diagnosis of liver fibrosis remains challenging because the condition often progresses without symptoms, while traditional assessments rely on invasive biopsy or costly imaging. Timely identification... Read more
Molecular Diagnostics
view channel
HPV Assay Gains Expanded CE Mark for Self-Collected Vaginal Samples
Cervical cancer is the fourth most common cancer in women and is largely preventable through vaccination and regular screening. However, even where organized screening programs exist, participation varies... Read more
Fully Automated Test Advances Hepatitis D Diagnosis and Monitoring
Hepatitis D virus infection can accelerate progression to cirrhosis and liver cancer, making timely diagnosis and longitudinal monitoring essential. Because hepatitis D depends on co-infection or superinfection... Read more
Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more
Hematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read more
Immunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read more
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read more
Pathology
view channel
Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
Mapping the spatial distribution of disease-relevant molecules within tissue remains a diagnostic challenge, particularly before alterations are visible by conventional microscopy. In Fabry disease, a... Read more
AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
Lung cancer is the leading cause of cancer-related death, and many patients require rapid genotyping to guide targeted therapy selection. Current workflows often rely on molecular tests that are costly,... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
